Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Aadi Bioscience Inc
Healthcare
P/NCAV
0.51x
Ticker
AADI
Exchange
NASDAQ
Country
United States
Close
1.84 $
Mkt Cap
49.5M $
EV
-13.4M $
NCAV Burn Rate
36.9%
Current Ratio
4.72
Debt/Equity
0.0
EV/REV
-0.55x
EV/EBIT
0.2x
EV/FCF
0.2x
Dilution
40.2% p.A
Total Net Income
-329.8M $
Cheapness
97.0%
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average